Exelixis is one of ten current favorite buys. x.com 

Significant discounts to broader pharmaceutical industry valuations on projected 2031 earnings make some high-quality mid-cap biotech stocks attractive. Many have cleared Phase 3 trials or reached more advanced stages, and some may reach profitability without more capital, an advantage if financing tightens. Selling these stocks to chase speculative biotech or large pharma at historically elevated multiples makes little sense. x.com 

AbbVie looks cheap at 16 times earnings, against the 20 times drugmakers usually get. Fair value is $285.91 to $363.89, based on 20 times next year's $16.25 a share give or take 12%, so the $261.83 price sits 8% below the low end; it turns expensive above $307.61. The range leans on forecasts, with forward earnings 60% above trailing. This is a levels-only read off reported earnings and estimates, with no fundamental work. x.com